Ocuphire Pharma
summary of positive phase results for eye drops | Ocuphire Pharma
Company
Deck Type
Deck date
March 2022
Slide
26 of 38
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
March 2021
summary of positive phase results for eye drops | Ocuphire Pharma
Related slides by other companies
Innoviva
Results
November 2023
top line summary positive phase results | Innoviva
HeartBeam
Results
November 2023
closing summary positive interactions with and internal milestones on track | HeartBeam
MindMed
Investor Presentation
November 2024
key highlights of program | MindMed
ATAI
Investor Presentation
October 2022
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights